Otsuka Holdings announces Phase 3 eGFR data for IgA nephropathy treatment drug
In VISIONARY trial interim analysis, eGFR change at 12 months showed better kidney function maintenance of 5.5 mL/min/1.73 m² than placebo group.
See the latest news and media coverage for Otsuka. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare holding company
otsuka.comLast updated
In short: Otsuka reported strong financial growth, expanded its psychiatric drug pipeline through major acquisitions, and secured key FDA drug approvals.
In VISIONARY trial interim analysis, eGFR change at 12 months showed better kidney function maintenance of 5.5 mL/min/1.73 m² than placebo group.
US subsidiary OPFA conducts $130 million capital increase to OCNA. Aimed at strengthening business foundation, no impact on performance.
From April 1 to 30, 2026, 783,900 shares were purchased on the market for 8.49 billion yen. Cumulative acquisition of 1,596,600 shares.
Revenue 630,342 million yen (up 8.2%), quarterly profit attributable to owners of the parent 98,348 million yen (up 15.7%).
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
Detailed price information for Otsuka Holdings CO Ltd (OTSKF) from The Globe and Mail including charting and trades.
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Otsuka Holdings Co ( (JP:4578)) just unveiled an announcement. Otsuka Holdings...
Detailed price information for Otsuka Holdings CO Ltd (OTSKF) from The Globe and Mail including charting and trades.
Track Otsuka and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Otsuka and other trending companies.